Emprila 5g

Indication
Indicated as a topical anesthetic for use on normal intact skin for local analgesia, genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.

Dosage and administration
A thick layer of Emprila cream is applied to intact skin and covered with an occlusive dressing.

Minor Dermal Procedures: For intravenous cannulation and venipuncture, apply 2.5 grams of Emprila cream over 20 – 25cm2 of skin surface for at least 1 hour.

Major Dermal Procedures: For more painful dermatological procedures involving a larger skin area, apply 2grams of Emprila cream per 10cm2 of skin and allow to remain in contact with the skin for at least 2 hours.

Adult Male Genital Skin: As an adjunct prior to local anesthetic infiltration, apply a thick layer of Emprila cream to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of Emprila cream. Adult Female Patients – Genital

Mucous Membranes: For minor procedures on the female external genitalia, such as removal of condylomata acuminata, as well as for use as pretreatment for anesthetic infiltration, apply a thick layer (5- 10grams) of Emprila cream for 5 to 10 minutes. Occlusion is not necessary for absorption, but may be helpful to keep the cream in place. Patients should be lying down during the Emprila cream application, especially if no occlusion is used. The procedure or the local anesthetic infiltration should be performed immediately after the removal of Emprila cream.

Pediatric Patients: The following are the maximum recommended doses, application areas and application times for Emprila cream based on a child’s age and weight:

Please note: If a patient greater than 3 months old does not meet the minimum weight requirement, the maximum total dose of Emprila cream should be restricted.

Contraindications, warnings, etc
Contraindication: It is contraindicated in patients with a known history of hypersensitivity of local anesthetics of the amide type.

Warnings and precautions: Absorption from wound surfaces and mucous membranes is relatively high, especially in the bronchial tree. Emprila cream should be used with caution in patients with traumatised mucosa and/or sepsis in the region of the proposed application. If the dose or site of administration is likely to result in high blood levels, cream should be used cautiously in patients with epilepsy, impaired cardiac condition, bradycardia, impaired hepatic function and in severe shock. The use of oropharyngeal topical anesthetic agents may interfere with swallowing and thus enhance the danger of aspiration. This is particularly important in children because of their frequency of eating. Numbness of the tongue or buccal mucosa may increase the danger of biting trauma.

Drug interactions: Cream should be used with caution in patients receiving antiarrhythmic drugs, such as tocainide, since the toxic effects are additive.

Use in pregnancy and lactation: There is no, or inadequate, evidence of safety of the drug in human pregnancy but it has been in wide use for many years without apparent ill consequence. If drug therapy is needed in pregnancy, this drug can be used if there is no safer alternative. Cream enters the mothers milk, but in such small quantities that there is generally no risk of affecting the child at therapeutic dose levels.

Side effects: Nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions, unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiac arrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema).